Key facts
- This page summarizes Bain Capital Life Sciences Investors, LLC's Form 4 filing for SpringWorks Therapeutics, Inc. (SWTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 12 Aug 2021, 20:38.
Bain Capital Life Sciences Investors, LLC - 10 Aug 2021 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- SWTX
- Reported as of
- 10 Aug 2021
- Net transaction value
- -$70,250,000
- SEC form
- 4
- Accepted by SEC
- 12 Aug 2021, 20:38:04 UTC
- Prior SEC filing
- 21 Jul 2021
- Next SEC filing
- 05 Nov 2021
- Source filing
- View source filing
- Reporting owner signature
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, By: /s/ Chris Green, Title: Managing Director
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Bain Capital Life Sciences Investors, LLC filed Form 4 for SpringWorks Therapeutics, Inc. (SWTX) on 12 Aug 2021.
Change
- Previous filing in this sequence was filed on 21 Jul 2021.
- Current net transaction value: -$70,250,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SWTX
transaction
Common Stock
Sale
- Transaction value
- $70,250,000
- Shares
- -1,000,000
- Change %
- -17%
- Price
- $70.25
- Shares after
- 4,831,307
- Date
- 10 Aug 2021
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3
SWTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,106
- Date
- 10 Aug 2021
- Ownership
- Direct
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents shares of common stock held directly by BC SW, LP.
Footnote F2
Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, LP. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, LP. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein.
Footnote F3
Jeffrey Schwartz is a director of the Issuer.
Footnote F4
Represents a restricted stock award held directly by Jeffrey Schwartz.